Phase II Study of Additional Treatment in Patients With Non-Hodgkin Lymphoma Shows No Significant Benefit
Tuesday, September 19, 2017
A phase II trial reported in the Journal of Clinical Oncology by John P. Leonard, M.D., and collaborators showed no significant progression-free survival benefit of adding bortezomib to R-CHOP.
